Please login to the form below

Not currently logged in
Email:
Password:

MS Society condemns government for lack of action

The Multiple Sclerosis Society in the UK is claiming that the government failed to find out the true cost of prescription charges despite a commitment made a year ago
The Multiple Sclerosis (MS) Society in the UK is claiming that the government failed to find out the true cost of prescription charges despite a commitment made a year ago, and is calling for free prescriptions for people with long-term health problems.

A coalition of charities, including the MS Society, says the government must now act urgently to make prescriptions free for people suffering from conditions that require long-term care, such as MS. The UK-based charity says that despite a promise by ministers in July 2007 to consult the public on prescription charges, the government has failed to take any action in the 12 months since that pledge was made.

A report by the Health Select Committee in 2006 sparked initial calls for a review of prescription charges. The list of medical conditions that entitle patients to free medication on the NHS has not been revised since 1968. At present, the only way for someone with a long-term medical problem to qualify for free prescriptions is through low income or age.

"The inaction of the government is deplorable and we are calling on MPs to support the coalition and highlight the urgent need for the review of prescription charging," said Dan Berry, head of policy and campaigns at the MS Society. "For people living with long-term conditions, prescription charges are yet another long-term financial burden on top of other costs associated with illness and disability, which can often include a lack of employment."

22nd July 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Clark Health Communications

Clark Health Communications (CHC) is an independent, award-winning health and medical communications agency. Our collaboration with experts and advocates enhances...

Latest intelligence

Theresa Heggie
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
Theresa Heggie talks about the biotech’s 16-year path to market, and the promise of its ‘gene silencing’ medicines...
patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...

Infographics